Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk

Author： Younk Lisa M   Uhl Lisa   Davis Stephen N  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.6, 2011-06, pp. : 753-763

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F   Holst Jens J  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive

By Dormandy John  

Drug Safety, Vol. 32, Iss. 3, 2009-01 ,pp. : 187-202

Adis International

Access to resources Recommend Favorite

Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

By Forst Thomas   Pfützner Andreas  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2281-2296

Informa Healthcare

Access to resources Recommend Favorite

Safety and Tolerability of Acarbose in the Treatment of Type 1 and Type 2 Diabetes Mellitus

By Neuser Dieter  

Clinical Drug Investigation, Vol. 25, Iss. 9, 2005-01 ,pp. : 579-587

Adis International

Access to resources Recommend Favorite

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update

By Marcel M.C. Hovens   Jouke T. Tamsma   Edith D. Beishuizen   Menno V. Huisman  

Drugs, Vol. 65, Iss. 4, 2005-01 ,pp. : 433-445

Adis International

Access to resources Recommend Favorite